The Insider: Meet the CEOs – 17 August

Adherium provides connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Founded in 2001 and listed on the ASX in 2015, the company’s strategy is focused on the digital health landscape – a US$34 billion market opportunity. Adherium’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients’ use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and Chronic Obstructive Pulmonary Disease (COPD), and reducing healthcare costs. In 2021, Adherium was awarded a supply contract with AstraZeneca for a bespoke version of its Hailie sensor and software solution for its US study.

EBR Systems provides safe, cost-effective and reliable therapies using wireless cardiac stimulation for millions of patients suffering from cardiac rhythm diseases. The company’s WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle (LV). The WiSE technology platform provides EBR with an initial addressable market of US$2.5 billion with rapid adoption of leadless devices supporting strong growth. The company’s technology is protected by over 97 issued patents globally and currently has no direct competitors known to be developing leadless LV pacing technology for Cardiac Resynchronisation Therapy (CRT).